Early research (Phase 1)Study completedNCT02546167What this trial is testingCART-BCMA Cells for Multiple MyelomaWho this might be right forMultiple Myeloma University of Pennsylvania 25
Testing effectiveness (Phase 2)Study completedNCT00806767What this trial is testingFludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological CancerWho this might be right forChronic Myeloproliferative DisordersLeukemiaLymphoma+3 more Institut Paoli-Calmettes 82
Not applicableStudy completedNCT00376922What this trial is testingMusic in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other DiseasesWho this might be right forChronic Myeloproliferative DisordersLeukemiaLymphoma+7 more Wake Forest University Health Sciences 65
Early research (Phase 1)Looking for participantsNCT04771572What this trial is testingStudy of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.Who this might be right forNon Hodgkin LymphomaRichter TransformationMultiple Myeloma+10 more Newave Pharmaceutical Inc 100
Early research (Phase 1)Not Yet RecruitingNCT06500507What this trial is testingQLS4131 in Patients With Recurrent or Refractory Multiple MyelomaWho this might be right forRelapsed or Refractory Multiple Myeloma Qilu Pharmaceutical Co., Ltd. 90
Not applicableLooking for participantsNCT05053607What this trial is testingReal World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with IsatuximabWho this might be right forMultiple MyelomaRefractory Multiple Myeloma Pack Health 50
Very early researchNot Yet RecruitingNCT07399444What this trial is testingA Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001）Who this might be right forMultiple Myeloma (MM) Institute of Hematology & Blood Diseases Hospital, China 38
Early research (Phase 1)Study completedNCT02101944What this trial is testingWild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaWho this might be right forAnemiaRecurrent Multiple MyelomaRefractory Multiple Myeloma National Cancer Institute (NCI) 12
Not applicableNot Yet RecruitingNCT07713511What this trial is testingINfections in Patients Treated With CAR-TWho this might be right forRelapsed Multiple MyelomaRefractory Multiple MyelomaB-Cell Non-Hodgkin Lymphoma+2 more IRCCS Azienda Ospedaliero-Universitaria di Bologna 290
Testing effectiveness (Phase 2)UnknownNCT00334932What this trial is testingDoxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple MyelomaWho this might be right forMultiple Myeloma and Plasma Cell Neoplasm Herbert Irving Comprehensive Cancer Center 32
Testing effectiveness (Phase 2)Ended earlyNCT02079519What this trial is testingAvastin (Bevacizumab) in Patients With Multiple MyelomaWho this might be right forMultiple Myeloma Hoffmann-La Roche 10
Testing effectiveness (Phase 2)Ended earlyNCT03837509What this trial is testingINCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple MyelomaWho this might be right forRelapsed or Refractory Multiple Myeloma Incyte Corporation 15
Large-scale testing (Phase 3)WithdrawnNCT05461209What this trial is testingComparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple MyelomaWho this might be right forRelapsed/ Refractory Multiple Myeloma Janssen Research & Development, LLC
Testing effectiveness (Phase 2)Looking for participantsNCT07479979What this trial is testingStudy of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple MyelomaWho this might be right forRelapse Multiple MyelomaRefractory Multiple Myeloma Natalie Callander 62
Early research (Phase 1)Study completedNCT01330173What this trial is testingVismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple MyelomaWho this might be right forDS Stage I Plasma Cell MyelomaDS Stage II Plasma Cell MyelomaDS Stage III Plasma Cell Myeloma+1 more National Cancer Institute (NCI) 50
Early research (Phase 1)Looking for participantsNCT05836896What this trial is testingA Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell MalignanciesWho this might be right forNeoplasmsRelapsed Diffuse Large B-cell Lymphoma (DLBCL)Refractory Diffuse Large B-cell Lymphoma (DLBCL)+2 more Technische Universität Dresden 16
Testing effectiveness (Phase 2)Study completedNCT00047203What this trial is testingFlavopiridol in Treating Patients With Relapsed or Refractory Multiple MyelomaWho this might be right forRefractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple Myeloma+1 more National Cancer Institute (NCI) 35
Early research (Phase 1)Study completedNCT00511082What this trial is testingPhase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple MyelomaWho this might be right forNon-Hodgkin's Lymphoma(NHL)Multiple Myeloma Otsuka Beijing Research Institute 7
Early research (Phase 1)Ended earlyNCT04171843What this trial is testingA Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple MyelomaWho this might be right forRelapsed/Refractory Multiple Myeloma Precision BioSciences, Inc. 48
Very early researchWithdrawnNCT02971410What this trial is testingSimvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple MyelomaWho this might be right forRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma Wake Forest University Health Sciences